Historical background
Graft-versus-host reactions (GVHR) after bone marrow transplantation were first observed in mouse recipients of bone marrow and spleen from donor mice ofdifferent strains. The condition was described by Barnes and Loutit in 19541: affected mice would survive the initial period ofmyelosuppression following irradiation (primary disease) and later, between three to six weeks after transplantation, develop a debilitating, wasting condition initially called secondary disease. For some years there was a debate about the nature of the GVHR because it was not clear whether the disease was a host-versus-graft or graft-versus-host effect. After a series of conflicting experiments, the demonstration by van Bekkum2 that GVHR severity was directly related to the number of splenic lymphocytes grafted, provided firm evidence that the disease was related to an immune effect of the graft against the host. Later, Trentin and Judd3 demonstrated in mice the complementary finding that lymphocyte depletion of bone marrow resulted in transplantation across major histocompatibility boundaries without graft-versus-host disease (GVHD).
At the end of the 1950s, some of the first experimental bone marrow transplants (BMT) in man were carried out in patients with end-stage leukaemia. In the absence of any detailed knowledge of histocompatibility, early attempts at human BMT were curtailed by the appearance of severe and often fatal human secondary disease4. This limitation led to restriction of bone marrow transplantation to the rare instances where an identical twin donor was available and to a brief but largely unsuccessful period of autologous bone marrow transplan-tation5'6. Following the description of the HLA system and the development of compatibility testing with the mixed lymphocyte culture introduced by Bach7, the-p-ossibility of selecting histocompatible matched donors for allogeneic bone marrow transplants led to a reappraisal of allogeneic BMT in the 1970s. It soon became apparent that even when using selected histocompatible matched donors, identical by HLA-A and B typing and mixed lymphocyte culture, GVHD often occurred and could be fatal. Studies with dog transplants by Storb et al. in Seattle8 led to the introduction of methotrexate as an agent which was believed to modify the severity of GVHD. During this time GVHD became better recognized and described clinically. General improvements in the management of BMT recipients, including better control of infection together with the introduction of new drugs such as cyclosporin A, led to more successful management of GVHD9. In the Graft-versus-host disease in man Acute GVHD This typically occurs 7-10 days after BMT and may occur sooner in recipients of HLA mismatched transplants. Characteristically there is a fever associated with a coarse maculopapular rash occurring on the face, palms, soles and extensor aspects of the limbs. Alternatively, the rash may present as a generalized erythema or a maculopapular rash affecting the trunk (Figure 1 ). The untreated condition may progress to a severe exfoliative erythroderma. As the rash subsides, the skin exfoliates and may become irregularly pigmented or depigmented. The gastrointestinal tract is frequently affected, the condition developing usually after the onset of the rash with profuse diarrhoea, abdominal cramps and vomiting, progressing to severe fluid protein and blood loss with generalized wasting, complicated by secondary infection from invading bowel organisms. The liver may be affected with a mixed hepatocellularobstructive pattern. These abnormalities may progress imperceptibly to a chronic GVHD with persisting intrahepatic obstruction ( Figure 2 ). Haematological reconstitution usually accompanies the onset of acute GVHD, but typically there is a lymphopenia. In patients with Fanconi's aplastic anaemia, a hyperacute GVHD has been described where toxic epidermal necrolysis beginning very early post-graft affects the skin, mucous membranes, conjunctiva, bladder and gut epithelium. There is generalized exfoliation of all epithelial and endothelial surfaces. This condition is a medical emerg- Chronic GVHD Chronic GVHD usually occurs after an episode of acute GVHD, either developing imperceptibly from acute GVHD or after a period of quiescence. In about 15% of cases, however, it occurs de novo. Typically it presents about 30 days following BMT with a pseudofollicular rash, sometimes violaceous in colour, affecting the face and extensor surfaces or becoming generalized. Mouth lesions identical to those seen in lichen planus are frequently present, together with loss of papillae on the tongue and oral ulceration ( Figure 3 ). The condition is associated with a sicca syndrome leading to xerostomia and xerophthalmia. Nail dysplasia, chronic exfoliative dermatitis and alopecia also occur. The condition may progress to a generalized scleroderma, particularly affecting the skin, exocrine glands and gastrointestinal tract (Figure 4 ). Malabsorption and weight loss can become major complications. The liver may also be affected with a progressive fibrosis associated with a 'vanishing bile duct syndrome' and intrahepatic obstruction which can progress to fatal liver failure. Other complications include autoimmune haemolytic anaemia, dyspigmentation, lung fibrosis and obstructive bronchiolitis. The process is accompanied by a profound depression of cellmediated immunity and immunoglobulin production, which encourages reactivation of viruses such as herpes simplex, varicella zoster and cytomegalovirus and facilitates opportunistic bacterial and fungal infections. Both acute and chronic GVHD are associated with a mortality of 10%12. mouth, showing In the liver periportal necrosis is characteristic and the condition may progress with increasing fibrosis and bile duct damage to chronic liver GVHD. Chronic GVHD is characterized by the presence of increasing amounts of collagen in the dermis, gut mucosa, exocrine glands, fascial sheaths and synovia. There is a variable lymphoid infiltrate. There is lymphoid atrophy with depopulation ofboth follicular and interstitial zones of lymph nodes and splenic atrophy. Sclerosis may become very profound, causing woody induration of the dermis with dense sheets of collagen.
Haematology
There are no characteristic changes in GVHD. Most commonly there is a lymphopenia and occasionally eosinophilia is seen in both acute and chronic GVHD. In severe or chronic GVHD there may be pancytopenia with a continuing requirement for platelet transfusion. Thrombocytopenia associated with GVHD carries a poor prognosis. Autoimmune destruction of blood cells may also occur with positive antiglobulin test, haemolytic anaemia, immune neutropenia and thrombocytopenia.
Immunopathology
Immunological,re4siWtution after allogeneic BMT is usually assodal4 with an imblance of T and B lymphocyte o i n (VIlD this abnormality is m u exaggdThere is a rapid risein -QKT8 subset with slo#*Wabseet recover of OKT4 subset adcompaniedby Bcelllymphopenia and hypogammaglobulinasmia with lymphoid atrophy".
Interestingly, immune reconstitution after T lympho-cyte depleted bone marrow where GVHD is rare or mild, is much more normal"5. There is a significant degree of immune deficiency in GVHD, especially when it becomes chronic, with increasing susceptibility to virus infections, particularly cytomegalovirus, herpes simplex virus and also bacterial agents. Splenic hypofunction seen after BMT, with increased susceptibility to pneumococcal infection, may be associated with the GVHD process. Despite the similarity of GVHD to autoimmune diseases such as systemic lupus erythematosus, tissue autoantibodies are not a feature of the condition. The nature of the sclerosis in chronic GVHD is not known, but serum of patients with GVHD contains circulating stimulators of bone marrow fibroblast growth which may be a substance related to platelet-derived growth factor16 Factors affecting GVHD A number of factors associated with GVHD have been identified both in animal and human grafts.
(1) Degree of antigenic disparity between donor and recipient: It has long been recognized that transplantation from identical twins is not usually accompanied by the GVHD syndrome although, interestingly, conditions resembling mild GVHD can occur'7, and GVHD syndromes have also been produced in rats with autologous bone marrow depleted of helper lymphocyte subsets"8. It is thus possible that GVHD syndrome may in part be related to immune imbalance. With increasing antigenic disparity between donor and recipient, GVHD incidence increases as shown in Table 1 . Human studies have shown that the HLA-B and DR are the transplantation antigens mainly involved, while a locus disparity may be less important in the causation of GVHD. (2) Number of lymphocytes transfused: Early experiments by van Bekkum2 showed a distinct relationship between the number of spleen cells grafted and the incidence and severity ofGVHD in mice. Trentin and Judd3 la-ter showed the corollary of these findings that lymphocyte depletion of mouse bone marrow by antiyinphocyte globulin could prevent GVHD. Muller-Ruchholz et al."9 extended these fundamental obserations to Tlymphocyte depleted rat into mouse xenogrUts, demonstrating that the creation of long-term GVHD-free chimeras was possible'9. These observations were of particular importance as this provided the basis of attempts to (3) Bacterial microflora: There is a close relationship between GVHD and bacterial contamination of the gut and skin. It has been recognized for some time that germ-free mice do not get GVHD22. This has led some groups to study the effect of gut microflora on GVHD and, by selective recontamination of mice, they have identified bacteria particularly likely to provoke GVHD23. Gut transplant experiments demonstrated that transplanted gut may suffer more bystander damage when the marrow transplant recipient gut is colonized by bacteria compared with when it is sterilized, but the correlation is not absolute. Such studies have led some groups to attempt complete or partial bacteriological decontamination of patients to prevent GVHD24 25. The limitations to this approach are the cost and duration of the isolation required and the inability to completely sterilize the human gut, except in the rare instances where a newborn infant with a severe combine immune deficiency disease can be delivered directly into a sterile isolater tent.
(4) Viral infection: There is a close association between certain viral infections and GVHD and both are interlinked, with immune deficiency of GVHD giving rise to viral expression and viral infections triggering GVHD processes. In particular, cytomegalovirus is closely related to GVHD. The immune stimulation of viral infections may lead to bystander damage ofother tissues, but much ofthis relationship is not clear. Viral damage and GVHD may also summate to produce major clinical problems, and the severe gastroenteritis caused by adenoviruses after BMT is an example of this.
(5) Age ofthe recipient: Increasing recipient age26 is a major risk factor in the incidence and severity of GVHD. The risk becomes particularly great in patients grafted over the age of 30 years, where GVHD has been associated with mortalities in the region of 60%.
(6) Previous treatment27: The immunosuppresive schedule used to prepare patients for BMT may lead to subliminal tissue damage to dividing cells in the gut and skin, increasing the damage caused by subsequent GVHD. Radiation conditioning schedules tend to induce more severe GVHD than those using cyclophosphamide alone.
Management of GVHD
The above factors determining GVHD are not easily controllable, and GVHD therefore remains a frequent problem requiring treatment or preferably prevention.
Treatment ofacute GVHD
The acute illness responds rapidly to steroids, with high-dose infusions ofmethyl prednisolone being particularly effective28. Many other agents have been used, but none of these approaches is entirely satisfactory since a proportion of patients fail to respond and may either succumb from complications associated with the acute reaction or from side effects of treatment with steroids and immunosuppresion, giving rise to lethal infection.
Treatment ofchronic G VHD Chronic GVHD responds to prednisolone in low doses in combination with azathioprine. In a classic study the Seattle group29 demonstrated the importance of using combinations of prednisolone and azathioprine to prevent the progression of chronic GVHD and drastically reduce its morbidity and mortality. Many other agents have been used with varying successes in the treatment of chronic GVHD but, again, no treatment is entirely satisfactory.
Prevention of GVHD Numerous attempts have been made to prevent GVHD. Early studies with methotrexate in dogs8 led to its widespread use in man but, in the absence of definitive controlled trials, it is difficult to know how effective this agent really is. Antilymphocyte globulin and steroids have been used, either singly or in combination with methotrexate30, and the Minnesota group has claimed good results with a combination ofthese three agents3". With the advent of the powerful immunosuppressive drug, cyclosporin, it was hoped that GVHD would be eliminated, but although it has been enthusiastically applied by a number ofteams as a prophylactic agent for GVHD, it is difficult to demonstrate any statistically significant improvement in the incidence and severity of GVHD or the overall mortality from bone marrow transplantation9 32'33.
The most significant impact upon GVHD prevention has come from the use of T lymphocyte depleted bone marrow. Early attempts using antilymphocyte globulin or cell density separation were unsuccessful because these techniques were inefficient34. Subsequently, however, Reisner et al. 35 successfully employed lectins and sheep red cells to select a stem cell enriched T lymphocyte depleted fraction of bone marrow, and demonstrated that efficient T lympho-cyte removal was associated with prevention of GVHD in leukaemia or immune-deficient recipients. With the advent of monoclonal antibodies, a variety of new techniques to deplete bone marrow of T lymphocytes emerged. Effective techniques usually employ cocktails of mouse monoclonal antibodies, including those with specificity equivalent to the OKT3 antibody"0. Cytotoxicity with mouse antibodies is weak unless rabbit complement is used. Some mouse antibodies do not fix human complement. However, the rat monoclonal antibody, Campath 1, has a useful antilymphocyte specificity, with the additional advantage that it fixes human complement, thus obviating the necessity to introduce foreign sera into bone marrow preparations ultimately destined for infusion in man36.
Other approaches currently in use are ricin conjugated anti-T cell antibodies37, countercurrent cell separation, and use of magnetic beads or colloids coated with antibody to trap and remove T lympho-cytes38. All these methods can be made extremely efficient, removing 2-3 logs ofT lymphocytes from the marrow while preserving normal stem cell function. Several clinical trials have now been reported using a variety of techniques. Such studies show that both acute and chronic GVHD can largely be eliminated by T cell depletion of donor marrow10'39.
However, the overall survival of recipients of T lymphocyte depleted marrow is not significantly better than historical controls because a new problem ofgraft rejection has emerged. This complication is rare after adequate preparation with whole body irradiation in recipients of undepleted bone marrow, but complicates transplants in a significant proportion of HLA matched transplants and a much greater number of mismatched transplants40'41. This rejection is believed to be due to failure by donor marrow infiusions depleted of T cells to eliminate residual host immunity at the time of the transplant. The rejection risk can be reduced by increasing the immunosuppression of the patient by increasing the radiation dose to the lymphoid system or increasing chemotherapy pretransplant. It is hoped that in the next few years the complication of rejection can be overcome completely, since T lymphocyte depletion will facilitate the safe transplantation of bone marrow from mismatched donors.
In conclusion, the complication of graft GVHD has stimulated much immunological research which may help to unravel pathological processes in other diseases such as lichen planus and autoimmune conditions. With better understanding ofthe GVHD process and new technology, it is not unreasonable to hope that the condition may become a rare and minor complication in matched grafts and the prevention of GVHD may open the way for safe BMT in mismatched transplants, thus giving major expansion to the scope of BMT for patients who at present do not have suitably matched sibling donors.
